CN104955484B - 用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法 - Google Patents

用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法 Download PDF

Info

Publication number
CN104955484B
CN104955484B CN201380053922.2A CN201380053922A CN104955484B CN 104955484 B CN104955484 B CN 104955484B CN 201380053922 A CN201380053922 A CN 201380053922A CN 104955484 B CN104955484 B CN 104955484B
Authority
CN
China
Prior art keywords
medicament
prostate
agent
specific antigen
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380053922.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104955484A (zh
Inventor
何国杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visen Medical Inc
Original Assignee
Visen Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visen Medical Inc filed Critical Visen Medical Inc
Publication of CN104955484A publication Critical patent/CN104955484A/zh
Application granted granted Critical
Publication of CN104955484B publication Critical patent/CN104955484B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201380053922.2A 2012-08-15 2013-03-15 用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法 Active CN104955484B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683305P 2012-08-15 2012-08-15
US61/683,305 2012-08-15
PCT/US2013/032200 WO2014028057A1 (en) 2012-08-15 2013-03-15 Prostate specific antigen agents and methods of using same for prostate cancer imaging

Publications (2)

Publication Number Publication Date
CN104955484A CN104955484A (zh) 2015-09-30
CN104955484B true CN104955484B (zh) 2019-01-15

Family

ID=48170795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380053922.2A Active CN104955484B (zh) 2012-08-15 2013-03-15 用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法

Country Status (7)

Country Link
US (1) US9371362B2 (enExample)
EP (1) EP2885006B1 (enExample)
JP (1) JP6370785B2 (enExample)
CN (1) CN104955484B (enExample)
AU (1) AU2013303233C1 (enExample)
CA (1) CA2882019C (enExample)
WO (1) WO2014028057A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104788433A (zh) 2005-09-02 2015-07-22 Visen医药公司 生物相容的含n,n-二取代磺酰胺的荧光染料标记
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
CA2749108C (en) 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
AU2012253502C1 (en) 2011-05-09 2017-12-14 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
CN104245954A (zh) 2012-03-30 2014-12-24 文森医学公司 细菌成像剂及其使用方法
WO2014028057A1 (en) 2012-08-15 2014-02-20 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
JP6606487B2 (ja) 2013-03-15 2019-11-13 ビセン メディカル， インコーポレイテッド ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素
CN105339436B (zh) 2013-03-15 2018-05-25 文森医学公司 4,4-二取代环己基桥连七甲川花菁染料及其应用
US9713649B2 (en) 2014-01-24 2017-07-25 The Cleveland Clinic Foundation PSMA-targeting imaging agents
US11154620B2 (en) 2015-08-18 2021-10-26 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
NZ739788A (en) 2015-08-18 2023-07-28 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
WO2019083990A2 (en) * 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)
WO2024181456A1 (ja) * 2023-02-27 2024-09-06 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
JPWO2024181455A1 (enExample) * 2023-02-27 2024-09-06
CN120752250A (zh) * 2023-02-27 2025-10-03 富士胶片株式会社 化合物及使用了该化合物的标记生物物质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028037A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels
WO2007028163A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible fluorescent imaging agents

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US4981977A (en) 1989-06-09 1991-01-01 Carnegie-Mellon University Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups
AU5085793A (en) 1992-09-04 1994-03-29 General Hospital Corporation, The Biocompatible polymers containing diagnostic or therapeutic moieties
US5808044A (en) 1993-01-22 1998-09-15 Pharmacia Biotech Inc. Indocarbocyanine and benzindocarbocyanine phosphoramidites
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US6008373A (en) 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
IT1276833B1 (it) 1995-10-09 1997-11-03 Sorin Biomedica Cardio Spa Coloranti fluorescenti della famiglia della solfo benz e indocianina
US6004536A (en) 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
JP2000508709A (ja) 1996-04-19 2000-07-11 アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド スクアラート染料類および蛍光配列決定法におけるそれらの使用
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5877310A (en) 1997-04-25 1999-03-02 Carnegie Mellon University Glycoconjugated fluorescent labeling reagents
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
ID24735A (id) * 1997-12-02 2000-08-03 Merck & Co Ltd Konjugat-konjugat yang berguna pada pengobatan kanker prostat
US6133445A (en) 1997-12-17 2000-10-17 Carnegie Mellon University Rigidized trimethine cyanine dyes
WO1999051702A1 (en) 1998-04-08 1999-10-14 Terpetschnig Ewald A Luminescent compounds
US6002003A (en) 1998-04-14 1999-12-14 Beckman Instruments, Inc. Cyanine dye activating group with improved coupling selectivity
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6174858B1 (en) * 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EP1065250B1 (en) 1999-07-02 2004-12-08 Visen Medical, Inc. New fluorescent cyanine labels containing a sulfamido linker arm
EP1219626B1 (en) 1999-09-20 2005-06-01 Fuji Photo Film Co., Ltd. Compounds for fluorescence labeling
AU2002236683A1 (en) 2000-10-27 2002-05-21 Beth Israel Deaconess Medical Center Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates
US6615063B1 (en) 2000-11-27 2003-09-02 The General Hospital Corporation Fluorescence-mediated molecular tomography
EP1209205A1 (en) 2000-11-28 2002-05-29 Innosense S.r.l. Improved process and method for the preparation of asymetric monofunctionalised indocyanine labelling reagents and obtained compounds
EP1221465A1 (en) 2001-01-03 2002-07-10 Innosense S.r.l. Symmetric, monofunctionalised polymethine dyes labelling reagents
US20030044353A1 (en) 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
AU2003207438A1 (en) 2002-01-02 2003-07-24 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
WO2003061711A2 (en) 2002-01-16 2003-07-31 Visen Medical, Inc. Chromophore probes for optical imaging
AU2003225763A1 (en) 2002-03-11 2003-09-29 Visen Medical, Inc. Optical imaging probes
EP1514093B1 (en) 2002-06-04 2021-04-28 Visen Medical, Inc. Imaging volumes with arbitrary geometries in non-contact tomography
US20060239916A1 (en) 2005-01-07 2006-10-26 Kai Licha Use of cyanine dyes for the diagnosis of proliferative diseases
TW200624440A (en) 2005-01-07 2006-07-16 Univ Kaohsiung Medical Prostate-specific antigen (psa) probes for optical imaging
US8173819B2 (en) 2005-09-02 2012-05-08 Visen Medical, Inc. Nicotinic and picolinic acid derived near-infrared fluorophores
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2007109364A2 (en) 2006-03-20 2007-09-27 The General Hospital Corporation Intramolecularly quenched fluorochrome conjugates and methods of use
US8221721B2 (en) 2007-02-09 2012-07-17 Visen Medical, Inc. Polycyclo dyes and use thereof
WO2008109832A2 (en) 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
CA2749108C (en) * 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
EP3673922A1 (en) 2008-03-14 2020-07-01 VisEn Medical, Inc. Integrin targeting agents and methods of using same
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
JP2013528379A (ja) 2010-05-21 2013-07-11 オームクス コーポレーション Ｐｓａ酵素活性アッセイによる癌の検出
AU2012253502C1 (en) 2011-05-09 2017-12-14 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
WO2014028057A1 (en) 2012-08-15 2014-02-20 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028037A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels
WO2007028163A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible fluorescent imaging agents

Also Published As

Publication number Publication date
JP2015532641A (ja) 2015-11-12
EP2885006B1 (en) 2018-08-08
WO2014028057A1 (en) 2014-02-20
US20140050662A1 (en) 2014-02-20
CA2882019A1 (en) 2014-02-20
EP2885006A1 (en) 2015-06-24
AU2013303233B2 (en) 2018-05-17
CA2882019C (en) 2021-02-09
AU2013303233C1 (en) 2018-08-23
AU2013303233A1 (en) 2015-03-05
CN104955484A (zh) 2015-09-30
US9371362B2 (en) 2016-06-21
JP6370785B2 (ja) 2018-08-08

Similar Documents

Publication Publication Date Title
CN104955484B (zh) 用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法
CN110204478A (zh) 碳酸酐酶靶向剂及其使用方法
US9913917B2 (en) Biocompatible fluorescent metal oxide nanoparticles
US9999687B2 (en) Fluorescent imaging agents
JP5586485B2 (ja) インテグリン標的化剤およびそれらを用いるｉｎｖｉｖｏおよびｉｎｖｉｔｒｏでの画像化方法
US9375493B2 (en) Bacterial imaging agents and methods of using same
CN103874512A (zh) 选择性递送分子及使用方法
Sun et al. Facile synthesis of melanin-dye nanoagent for NIR-II fluorescence/photoacoustic imaging-guided photothermal therapy
US20070098638A1 (en) Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications
CN107303388B (zh) 一种基于近红外染料-透明质酸复合物的诊断治疗制剂
JP2023536961A (ja) 癌の検出および処置のための方法および薬剤

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant